JPS6373964A - Freeze fine pulverization of crystal - Google Patents
Freeze fine pulverization of crystalInfo
- Publication number
- JPS6373964A JPS6373964A JP22071586A JP22071586A JPS6373964A JP S6373964 A JPS6373964 A JP S6373964A JP 22071586 A JP22071586 A JP 22071586A JP 22071586 A JP22071586 A JP 22071586A JP S6373964 A JPS6373964 A JP S6373964A
- Authority
- JP
- Japan
- Prior art keywords
- liquid
- gas
- refrigerant
- crystals
- frozen particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims description 55
- 238000010298 pulverizing process Methods 0.000 title claims description 19
- 239000007788 liquid Substances 0.000 claims description 115
- 239000003507 refrigerant Substances 0.000 claims description 78
- 239000002245 particle Substances 0.000 claims description 65
- 239000003814 drug Substances 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 19
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 239000007789 gas Substances 0.000 description 45
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- 238000002347 injection Methods 0.000 description 23
- 239000007924 injection Substances 0.000 description 23
- 239000000725 suspension Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000002156 mixing Methods 0.000 description 16
- 239000007921 spray Substances 0.000 description 15
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 229940106164 cephalexin Drugs 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 229910001873 dinitrogen Inorganic materials 0.000 description 10
- -1 cefatridine Chemical compound 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000010419 fine particle Substances 0.000 description 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 8
- 239000000417 fungicide Substances 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000005273 aeration Methods 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229960000210 nalidixic acid Drugs 0.000 description 4
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 239000002344 surface layer Substances 0.000 description 4
- 229960000278 theophylline Drugs 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003905 agrochemical Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000002917 insecticide Substances 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- IAQRGUVFOMOMEM-UHFFFAOYSA-N but-2-ene Chemical compound CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 229940042016 methacycline Drugs 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical compound CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- CRFFPDBJLGAGQL-UHFFFAOYSA-N 2-azaniumyl-3-[4-(trifluoromethyl)phenyl]propanoate Chemical compound OC(=O)C(N)CC1=CC=C(C(F)(F)F)C=C1 CRFFPDBJLGAGQL-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- IEMDOFXTVAPVLX-YWQHLDGFSA-N Leucomycin A1 Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 IEMDOFXTVAPVLX-YWQHLDGFSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000004104 Oleandomycin Substances 0.000 description 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000594009 Phoxinus phoxinus Species 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- ZCDNRPPFBQDQHR-SSYATKPKSA-N Syrosingopine Chemical compound C1=C(OC)C(OC(=O)OCC)=C(OC)C=C1C(=O)O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@H]2C[C@@H]3C(NC=4C5=CC=C(OC)C=4)=C5CCN3C[C@H]2C1 ZCDNRPPFBQDQHR-SSYATKPKSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- XSXCZNVKFKNLPR-SDQBBNPISA-N carbazochrome Chemical compound NC(=O)N/N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 XSXCZNVKFKNLPR-SDQBBNPISA-N 0.000 description 1
- 229960002631 carbazochrome Drugs 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 229940047526 cephalexin monohydrate Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000017168 chlorine Nutrition 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- 229960002925 clonidine hydrochloride Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 229960004244 cyclacillin Drugs 0.000 description 1
- HGBLNBBNRORJKI-WCABBAIRSA-N cyclacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C1(N)CCCCC1 HGBLNBBNRORJKI-WCABBAIRSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960003710 dantrolene sodium Drugs 0.000 description 1
- LTWQNYPDAUSXBC-CDJGKPBYSA-L dantrolene sodium hemiheptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1.C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1 LTWQNYPDAUSXBC-CDJGKPBYSA-L 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- DFBKLUNHFCTMDC-PICURKEMSA-N dieldrin Chemical compound C([C@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@H]2[C@@H]2[C@H]1O2 DFBKLUNHFCTMDC-PICURKEMSA-N 0.000 description 1
- 229950006824 dieldrin Drugs 0.000 description 1
- NGPMUTDCEIKKFM-UHFFFAOYSA-N dieldrin Natural products CC1=C(Cl)C2(Cl)C3C4CC(C5OC45)C3C1(Cl)C2(Cl)Cl NGPMUTDCEIKKFM-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229960000807 dihydroergotamine mesylate Drugs 0.000 description 1
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N dimethylacetylene Natural products CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960001149 dopamine hydrochloride Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 229950000501 gabexate Drugs 0.000 description 1
- DNTNDFLIKUKKOC-UHFFFAOYSA-N gabexate methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)[NH3+])C=C1 DNTNDFLIKUKKOC-UHFFFAOYSA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229960003884 hetacillin Drugs 0.000 description 1
- DXVUYOAEDJXBPY-NFFDBFGFSA-N hetacillin Chemical compound C1([C@@H]2C(=O)N(C(N2)(C)C)[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 DXVUYOAEDJXBPY-NFFDBFGFSA-N 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 229960002757 midecamycin Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- YGZIWEZFFBPCLN-UHFFFAOYSA-N n,3-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound OOC1CCOP(=O)(NCCCl)N1CCCl YGZIWEZFFBPCLN-UHFFFAOYSA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
- 229960002351 oleandomycin Drugs 0.000 description 1
- 235000019367 oleandomycin Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229960000293 pirenzepine hydrochloride Drugs 0.000 description 1
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229950006534 syrosingopine Drugs 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Abstract] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
産業上の利用分野
本発明は、医薬品、農薬等の薬物の結晶を微粉砕する方
法に関し、詳しくは、該結晶を特定の液状媒体とともに
凍結し噴射衝突させて微粒化する方法に関する。DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention relates to a method for finely pulverizing crystals of drugs such as pharmaceuticals and agricultural chemicals. Specifically, the present invention relates to a method of finely pulverizing crystals of drugs such as pharmaceuticals and agricultural chemicals. Regarding how to.
従来の技術
抽出又は合成、半合成法等により得られた医薬品、農薬
等は精製され、結晶として得られるが、これらの薬物は
さらに錠剤、散剤、頚粒剤等の製剤化のために結晶とし
て精製された薬物は、微粉砕する必要がある。Pharmaceuticals, pesticides, etc. obtained by conventional techniques such as extraction, synthesis, and semi-synthetic methods are purified and obtained as crystals, but these drugs are further processed as crystals to formulate tablets, powders, cervical tablets, etc. Purified drugs need to be finely ground.
従来、かかる微粉砕する方法としては、ボールミノベ振
動ボールミノペ衝撃式粉砕機、゛ジェット粉砕機等を用
いた方法が一般的である。Conventionally, as a method of pulverizing, a method using a ball minnow vibrating ball minope impact crusher, a jet pulverizer, etc. is common.
発明が解決しようとする問題点
しかし、ボールミル1振動ボールミルを用いた場合、ボ
ール相互の衝突により熱を発生するため、冷却水等で冷
却しつつ粉砕を行なう必要がある。Problems to be Solved by the Invention However, when a vibrating ball mill is used, the balls collide with each other and generate heat, so it is necessary to perform pulverization while cooling with cooling water or the like.
また、ボールが衝突により摩滅し、その摩滅粒が粉砕品
中に混入し、純粋な粉砕品が得られ難い。In addition, the balls are worn out due to collision, and the worn particles are mixed into the pulverized product, making it difficult to obtain a pure pulverized product.
更に、上記の粉砕機は構造も複雑であり、場合により、
粉砕機内部への粉体の付着が激しく、医薬品のように多
品種を少量粉砕するばあいにはかなりの不利益となって
いた。Furthermore, the structure of the above-mentioned crusher is complicated, and in some cases,
Powder adheres to the inside of the pulverizer, which is a considerable disadvantage when pulverizing a wide variety of products in small quantities, such as pharmaceutical products.
問題点を解決するための手段
本発明はかかる不利益のない薬物の結晶の粉砕方法を提
供することを目的とし、該目的は、薬物結晶を液状媒体
中に懸濁し500ミクロン径以下の液滴として、該媒体
とともに薬物結晶を該媒体の融点以下の低温に保持した
液化ガス冷媒中に投下して実質的に粒径500ミクロン
以下の薬物結晶含有微凍結粒とした後、該結晶含有微凍
結粒を噴射しfir突による衝撃力を与えて粉砕するこ
とにより達成される。Means for Solving the Problems The present invention aims to provide a method for crushing drug crystals without such disadvantages, and the object is to suspend drug crystals in a liquid medium and form droplets with a diameter of 500 microns or less. After dropping the drug crystals together with the medium into a liquefied gas refrigerant maintained at a low temperature below the melting point of the medium to form micro-frozen particles containing drug crystals with a particle size of 500 microns or less, This is achieved by injecting particles and applying impact force by fir impaction to crush them.
本発明によれば、薬物結晶は媒体とともに微凍結粒にさ
れる。即ち、硬く凍結した媒体中に挟み込まれているた
必、抵抗体に衝突させるか、微凍結粒同士をi(i突さ
せると、衝突する際に該凍結媒体が摩砕材として作用し
結晶を効率よく粉砕し、特に、結晶を5〜50ミクロン
以下に微粉砕するのに適している。According to the present invention, drug crystals are microfrozen with a medium. That is, if the slightly frozen particles are sandwiched in a hard frozen medium and are forced to collide with a resistor or collide with each other, the frozen medium acts as a grinding agent during the collision, causing the crystals to break down. It is suitable for efficient pulverization and is particularly suitable for pulverizing crystals to a size of 5 to 50 microns or less.
本発明は、結晶として精製される薬物であれば特に限定
されることなく適用することができ、例えば抗生物質(
アンピシリン、ヘタシリン、アモキシシリン、シクラシ
リン、カルベニシリン等またはその無毒性塩のペニシリ
ン系抗生物質、セファレキシン、セファゾリン、セファ
ロチン、セファトリジン、セフオキシチン等またはその
無毒性塩のセファロスポリン系抗生物質、パロモマイシ
ン、カナマイシン、アミカシン、ゲンタマイシン。The present invention can be applied without particular limitation as long as it is a drug that can be purified as a crystal. For example, antibiotics (
Penicillin antibiotics such as ampicillin, hetacillin, amoxicillin, cyclacillin, carbenicillin or their non-toxic salts, cephalosporin antibiotics such as cephalexin, cefazolin, cephalothin, cefatridine, cefoxitin or their non-toxic salts, paromomycin, kanamycin, amikacin, Gentamicin.
トブラマイシン等またはその無毒性塩のアミノ糖系抗生
物質、クロルテトラサイクリン、テトラサイクリン、ド
キシサイクリン、メタサイタリン等またはその無毒性塩
のテトラサイクリン系抗生物質、エリスロマイシン、オ
レアンドマイシン、ロイコマイシン、ジョサマイシン、
ミデカマイシン等またはその無毒性塩のマクロライド系
抗生物質、その他ポリミキシンB、コリスチン、サイク
ロセリン、ホスホマイシン、アンピシリンB、)リコマ
イシン、ナイスクチン等またはその無毒性塩等)、中枢
神経薬(ジアゼパム、ニスクシラム等の催眠鎮静剤、フ
ェニトイン、メプロバメート。Aminosugar antibiotics such as tobramycin or its non-toxic salts, chlortetracycline, tetracycline, doxycycline, metacycline antibiotics such as metacycline or its non-toxic salts, erythromycin, oleandomycin, leucomycin, josamycin,
Macrolide antibiotics such as midecamycin or its nontoxic salts, other polymyxin B, colistin, cycloserine, fosfomycin, ampicillin B, lycomycin, nyscutin, or its nontoxic salts), central nervous system drugs (diazepam, niskucilam, etc.) Hypnotic sedatives, phenytoin, meprobamate.
ニトラゼパム等の抗てんかん剤、アセトアミノフェノン
、インドメタシン、メフェナム酸、ジクロフェナック、
フルフェナム酸等の解熱鎮痛消炎剤等)、末梢神経薬(
プロ力イン、リドカイン等の局所麻酔剤、塩酸トリベリ
シン、ダントロレンナトリウム等の筋弛緩剤、アトロピ
ン、レボドパ等の自律神経用剤等)、循環器官用剤(ジ
キタソス。Antiepileptic drugs such as nitrazepam, acetaminophenone, indomethacin, mefenamic acid, diclofenac,
antipyretic analgesic antiinflammatory agents such as flufenamic acid), peripheral nerve drugs (
local anesthetics such as procotylin and lidocaine, muscle relaxants such as trivericin hydrochloride and dantrolene sodium, agents for autonomic nerves such as atropine and levodopa, etc.), agents for the circulatory system (Dikitasos, etc.).
ユビデカレノン等の強心剤、テオフィリン、スピロノラ
クトン、トリパミド等の利尿剤、レセルピン、塩酸クロ
ニジン、メチルドパ、シロシンゴピン等の血圧降下剤、
メシル酸ジヒドロエルゴタミン、メシル酸ジヒドロエル
ゴトキシン等の血管収縮剤、ルチン、カルバゾクロム等
の血管補強剤、ニトログリセリン、硝酸イソソルビトー
ル、ニフェジピン、ジピリダモール等の冠血管拡張剤、
その他ペントキシフィリン、チトクロームC,シチコリ
ン、塩酸ドパミン等)、呼吸器官用剤(エフェドリン、
コディン等のS、ft0if去たん剤、その他イソプロ
テレノール、クロモグリク酸、デキストロメトルファン
等)、消化器官用薬(アラントイン。Cardiac inotropes such as ubidecarenone, diuretics such as theophylline, spironolactone, and trypamide, antihypertensive agents such as reserpine, clonidine hydrochloride, methyldopa, syrosingopine,
Vasoconstrictors such as dihydroergotamine mesylate and dihydroergotoxine mesylate; vascular reinforcing agents such as rutin and carbazochrome; coronary vasodilators such as nitroglycerin, isosorbitol nitrate, nifedipine, and dipyridamole;
Others (pentoxifylline, cytochrome C, citicoline, dopamine hydrochloride, etc.), respiratory agents (ephedrine,
Codin and other S, ft0if expectorants, other isoproterenol, cromoglylic acid, dextromethorphan, etc.), digestive system drugs (allantoin, etc.).
塩酸ピレンゼピン、ウロガストロン、シメチジン等の消
化性潰瘍治療剤等)、代謝性医薬品(ビタミン82 、
ジアノコバラミン等のビタミン類、その他グルタチオン
、ATP、メシル酸ガベキサート等)、化学療法剤(ク
ロトリマゾール、ピロールニ) IJン、ナリジクス酸
、サルファ剤等)等の動物薬を含む医薬品、クエン酸鉄
、クエン酸ナトリウム、コハク酸、サッカリン酸ナトリ
ウム、酒石酸ナトリウム、ソルビン酸カリウム、ソルビ
ン酸ナトリウム、炭酸カルシウム、チアミン塩酸塩。peptic ulcer treatment agents such as pirenzepine hydrochloride, urogastrone, cimetidine, etc.), metabolic drugs (vitamin 82,
Vitamins such as dianocobalamin, other veterinary drugs such as glutathione, ATP, gabexate mesylate, etc.), chemotherapeutic agents (clotrimazole, pyrrolni, IJ, nalidixic acid, sulfa drugs, etc.), iron citrate, Sodium citrate, succinic acid, sodium saccharinate, sodium tartrate, potassium sorbate, sodium sorbate, calcium carbonate, thiamine hydrochloride.
乳酸カルシウム、乳酸鉄、パントテン酸カルシウム、リ
ボフラビン、リンゴ酸ナトリウム等の食品添加物、アル
ドリン、ディエルドリン、エディオン等の塩素系殺虫剤
やリン系殺虫剤、カルバミン酸エステル系殺虫剤、クロ
ルアニル、ジクロン等のキノン系殺菌剤、チオカルバミ
ン酸系殺菌剤。Food additives such as calcium lactate, iron lactate, calcium pantothenate, riboflavin, sodium malate, chlorine insecticides such as aldrin, dieldrin, edion, phosphorus insecticides, carbamate ester insecticides, chloranil, ziclone, etc. Quinone-based fungicide, thiocarbamate-based fungicide.
有機水銀系殺菌剤、有機スズ系殺菌剤、フェノール系殺
菌剤、トリアジン系殺菌剤等の農薬等が挙げられる。Examples include agricultural chemicals such as organic mercury fungicides, organic tin fungicides, phenol fungicides, and triazine fungicides.
また本発明における液状媒体としては、対象として用い
る薬物結晶を溶解しないかまたは溶解しても0.5%以
下の溶解性を示すもので、常温ないし室温にて液状であ
り、冷媒の沸点以上の温度にて融点を有する゛ものであ
れば何んら限定されるものではない。さらにこの媒体の
沸点としては低い温度のものほど除去し易く好ましく、
例えば水(mpO℃、bploO℃)または塩類水溶液
。In addition, the liquid medium used in the present invention is one that does not dissolve the target drug crystals or exhibits a solubility of 0.5% or less even if dissolved, is liquid at room temperature or room temperature, and has a temperature higher than the boiling point of the refrigerant. There are no limitations at all as long as it has a melting point at that temperature. Furthermore, the lower the boiling point of this medium, the easier it is to remove, and
For example water (mpO<0>C, bploO<0>C) or aqueous salt solutions.
エタノール(mp−114,5℃、bp78.3℃)。Ethanol (mp-114, 5°C, bp 78.3°C).
アリルアルコール(m p −129℃、bp97.1
℃)、イソブチルアルコール(mp−85,5℃。Allyl alcohol (mp -129℃, bp97.1
°C), isobutyl alcohol (mp-85, 5 °C).
bp68℃)、イソプロピルアルコール(mp−86,
0℃、bp82.0℃)、プロピルアルコール(mp−
126℃、bp97.4℃)、メタノール(mp−98
℃、bp64.6℃)等の低級アルキルアルコール類、
イソプロピルアミン(mp−101,2℃、bp33℃
)、エチルアミン(mp−83,3℃、bp16℃)、
ジエチルアミン(mp−48℃、bp55.9℃)、ジ
メチルアミン(mp−96℃、bp7℃)、ブチルアミ
ン(mp−50,5℃、bp77.8℃) 、 ter
t−ブチルアミ7(mp−67,5℃、bp45.2℃
)、プロピルアミン(mp−83,0℃、bp47.8
℃)。bp68℃), isopropyl alcohol (mp-86,
0℃, bp82.0℃), propyl alcohol (mp-
126℃, bp97.4℃), methanol (mp-98
℃, bp64.6℃), lower alkyl alcohols,
Isopropylamine (mp-101, 2℃, bp 33℃
), ethylamine (mp-83, 3°C, bp 16°C),
Diethylamine (mp-48°C, bp 55.9°C), dimethylamine (mp-96°C, bp 7°C), butylamine (mp-50,5°C, bp 77.8°C), ter
t-Butylamide 7 (mp-67,5℃, bp45.2℃
), propylamine (mp-83,0℃, bp47.8
℃).
メチルアミン(mp−92,5℃、bp−5,5℃)等
の低級アルキルアミン類、アセトン(mp−94℃、b
p56.3℃)、エチルメチルケトン(m p −’8
6.6℃、bp79.4℃)、ジエチルケ)ン(mp−
42,0℃、bplol、7℃)等の低級アルキルケト
ン類、エチルエーテル(mp−116,3℃、bp34
.6℃)、プロピルエーテル(mp−122℃、bp9
0.6℃)等の低級アルキルエーテル類、エチレンジク
ロライド(mp−35,3℃、bp83.7℃) 、
tert−ブチルクロライド(mp−28,5℃、bp
51.0℃)、プロピルクロライド(mp−122,8
℃、bp46.4℃)、メチレンジクロライド(mp−
96℃。Lower alkylamines such as methylamine (mp-92.5°C, bp-5.5°C), acetone (mp-94°C, b
p56.3°C), ethyl methyl ketone (m p -'8
6.6℃, bp79.4℃), diethylkene (mp-
Lower alkyl ketones such as 42,0℃, bplol, 7℃), ethyl ether (mp-116,3℃, bp34
.. 6°C), propyl ether (mp-122°C, bp9
Lower alkyl ethers such as 0.6°C), ethylene dichloride (mp-35, 3°C, bp 83.7°C),
tert-butyl chloride (mp-28, 5°C, bp
51.0°C), propyl chloride (mp-122,8
℃, bp46.4℃), methylene dichloride (mp-
96℃.
b p 41.6℃)、クロラール(mp−57,5、
℃。b p 41.6°C), chloral (mp-57.5,
℃.
bp98℃)、りooホルム(mp−63,5℃。bp98℃), riooform (mp-63, 5℃).
b p 61.2℃)、四塩化炭素(mp−22,6℃
。b p 61.2°C), carbon tetrachloride (mp-22,6°C
.
b p 76.7℃) 、 tert−ブチルクロライ
ド(mp−20℃、bp73.3℃)、メチルブロマイ
ド(mp−93℃、bp4.5℃)、メチレンブO’フ
ィト(mp−52,8℃、bp97℃)、トリクロoエ
チレン(mp−73℃、bp87.2℃)、フルオロヘ
ンゼア(mp−41,2℃、bp85℃)、ホスゲ7(
mp−128℃、bp8℃〉等のハロゲン化炭化水素類
、酢酸メチル(mp−98℃。bp 76.7°C), tert-butyl chloride (mp-20°C, bp 73.3°C), methyl bromide (mp-93°C, bp 4.5°C), methylenebuO'phyto (mp-52, 8°C, bp 97°C), trichloroethylene (mp-73°C, bp 87.2°C), fluorogenzea (mp-41,2°C, bp 85°C), Phosge 7 (
mp-128°C, bp 8°C> and other halogenated hydrocarbons, methyl acetate (mp-98°C).
b p 57.1℃)、プロピオン酸エチル(mp−7
3,9℃、bp99.1℃)、プロピオン酸メチル(m
p−87,5℃、bp79.7℃)等の低級脂肪酸エス
テル類、インブチレン(mp−146,8t、bp−6
,6℃)、イソプレン(mp−120t、bp34.5
℃)、シクロヘキセ7(mp−103,7℃、bp83
.3℃)、シクロヘキサン(mp’D、D℃、bp80
.8℃)シクロヘンタンエン(mp−85℃、bp41
℃)、シクロヘンタン(mp−93,3℃、bp49℃
)1シクoペンテン(mp−93,3℃、bp44℃)
、2.2−ジメチルブタ7(mp−98,2℃、bp4
9.7℃)、ネオヘンタン(mp−19,8℃、bpl
。b p 57.1°C), ethyl propionate (mp-7
3.9°C, bp99.1°C), methyl propionate (m
Lower fatty acid esters such as p-87,5℃, bp79.7℃), imbutylene (mp-146,8t, bp-6
, 6°C), isoprene (mp-120t, bp34.5
°C), cyclohexe 7 (mp-103, 7 °C, bp83
.. 3℃), cyclohexane (mp'D, D℃, bp80
.. 8℃) cyclohentanene (mp-85℃, bp41
℃), cyclohentane (mp-93, 3℃, bp 49℃
) 1 pentene (mp-93, 3℃, bp44℃)
, 2,2-dimethylbuta7 (mp-98, 2°C, bp4
9.7℃), neohentane (mp-19.8℃, bpl
.
℃)、ブタン(mp−135℃、bp−0,5℃)。°C), butane (mp-135 °C, bp-0,5 °C).
2−ブテン(mp−127℃、bp1℃)、ヘン、yン
(mp−90℃、bp98.4℃)、ベンゼン(mp5
.5℃、bpgo、t℃)、ペンタン(mp−130,
8℃、bp36.2℃)等の飽和、不飽和または環式炭
化水累類の単独または2種以上の混合溶媒が挙げられる
。2-butene (mp-127°C, bp1°C), hene, yn (mp-90°C, bp98.4°C), benzene (mp5
.. 5°C, bpgo, t°C), pentane (mp-130,
8° C., bp 36.2° C.), a single solvent or a mixed solvent of two or more of saturated, unsaturated or cyclic hydrocarbons may be used.
又、結晶含有凍結粒の大きさ及び形状は、公知のノズル
から噴出可能なものであれば特に固定されることはない
。但し、粒径が500ミクロン以上であると噴出に多大
のエネルギーを要するため、実質上粒径が500ミクロ
ン以下の凍結粒であることが好ましく、特に、表面に漣
が形成された冷媒に投下することにより製造された粒径
500ミクロン以下のさらさらした水球であることが好
ましい。Further, the size and shape of the crystal-containing frozen particles are not particularly fixed as long as they can be ejected from a known nozzle. However, if the particle size is 500 microns or more, it will take a lot of energy to blow it out, so frozen particles with a particle size of 500 microns or less are preferable, especially if they are dropped onto a refrigerant with ripples formed on the surface. Preferably, it is a free-flowing water sphere with a particle size of 500 microns or less produced by this method.
本発明において好ましく用いられる粒径500ミクロン
以下の水球を作るためには、該冷媒の表面に高さ5+n
n+〜20mmの漣を形成しておくことが必要である。In order to make water spheres with a particle size of 500 microns or less, which is preferably used in the present invention, a height of 5+n is required on the surface of the refrigerant.
It is necessary to form a ripple of n+ to 20 mm.
又、冷媒は、用いる媒体の融点以下で液化するものであ
れば特に限定されることはないが、一般に、液体窒素、
液体ヘリウム、液体アルゴン、液体空気等の一150℃
以下の冷媒が好ましい。In addition, the refrigerant is not particularly limited as long as it liquefies below the melting point of the medium used, but generally liquid nitrogen,
-150℃ of liquid helium, liquid argon, liquid air, etc.
The following refrigerants are preferred.
但し、連続的にさらさらした水球を作るためには、冷媒
の温度は媒体の融点よりもさらに10〜20℃だけ低く
保っておくことが好ましい。However, in order to continuously produce smooth water spheres, it is preferable to keep the temperature of the refrigerant 10 to 20°C lower than the melting point of the medium.
又、薬物結晶含有凍結粒の結晶含有率が高すぎると凍結
媒体の摩砕材としての機能が低下し、また、該結晶含有
率低すぎると薬物結晶に直接の衝撃力がかえって伝わり
にくくなるので、該結晶含有量は、0.005g/mf
l〜0.5g/mj2であることが好ましい。In addition, if the crystal content of the frozen particles containing drug crystals is too high, the function of the freezing medium as a grinding agent will be reduced, and if the crystal content is too low, it will be difficult for direct impact force to be transmitted to the drug crystals. , the crystal content is 0.005g/mf
It is preferable that it is l~0.5g/mj2.
又、結晶含有凍結粒の噴射位置と衝突面との間隔は薬物
結晶含有凍結粒の形状、大きさ、噴射速度によって適宜
選択可能であるが、通常例えば10++on〜100m
mであることが好ましく、噴射時の該結晶含有凍結粒は
前記の冷媒により融点以下の品温に保持して噴出せしめ
ればよい。Further, the distance between the injection position of the crystal-containing frozen particles and the collision surface can be appropriately selected depending on the shape, size, and injection speed of the drug crystal-containing frozen particles, but is usually, for example, 10++ on to 100 m.
The temperature of the crystal-containing frozen particles at the time of injection is maintained at a temperature below the melting point by the above-mentioned refrigerant and then ejected.
上記衝突面については、抵抗体としての硬質板が例示さ
れるもので、これは板状であってもよく、曲面状の種々
の形状のものであってもよく、さらにその材質は、硬度
の高いセラミック板、金属製剛板等が好ましく用いられ
る。As for the above-mentioned collision surface, a hard plate as a resistor is exemplified, and this may be plate-shaped or curved in various shapes. A high ceramic plate, a rigid metal plate, etc. are preferably used.
また硬質板の代りに、第9図に示す如く、微凍結粒を少
なくとも2以上の噴射装置91から噴出して微凍結粒同
士を噴射衝突せしめてもよい。その際噴射角度αは特に
限定されるものではないが衝突面との距離りとして2以
上の噴射装置91からの噴射交叉点とする場合、60〜
120度程度の角度にて衝突せしめればよい。Moreover, instead of the hard plate, as shown in FIG. 9, the finely frozen particles may be ejected from at least two or more injection devices 91, and the finely frozen particles may be jetted and collided with each other. In this case, the injection angle α is not particularly limited, but when the distance from the collision surface is set to the intersection point of injections from two or more injection devices 91, the injection angle α is 60 to
The collision may be made at an angle of about 120 degrees.
さらにこのようにて衝突せしめた後、その後部に抵抗体
を設置して二段衝突せしめてもよいものである。Furthermore, after the collision is made in this manner, a resistor may be installed at the rear of the collision to cause a two-stage collision.
さらに上述の如くして噴射衝突せしめた微凍結粒は、衝
突により破砕されると同時に噴射装置内にて舞っている
ため、例えば第10図に示す如くの試料回収装置を用い
て、この装置内にて噴射せしめることが好ましい。この
試料回収装置(直径500mm、高さ110mm)の中
心部に上記の噴射装置を1または2以上設置し、次いで
噴射せしめることにより、噴出された微凍結粒は衝突し
た後水平方向に拡散し、かつその仕切板94により減圧
、減速されて、破砕された微凍結粒が回収される。さら
にこのようにして回収された破砕微凍結粒は、必要に応
じて一旦解凍後、再度微凍結粒となして、2回以上噴射
衝突せしめて破砕させてもよい。Furthermore, since the finely frozen particles jetted and collided as described above are crushed by the collision and are also floating inside the jetting device, for example, using a sample collection device as shown in FIG. It is preferable to inject it at. By installing one or more of the above-mentioned injection devices in the center of this sample collection device (diameter 500 mm, height 110 mm) and then injecting the particles, the ejected finely frozen particles collide and then spread in the horizontal direction. The pressure is reduced and the speed is reduced by the partition plate 94, and the crushed finely frozen particles are recovered. Further, the crushed finely frozen particles thus collected may be thawed once as necessary, and then re-formed into finely frozen particles and crushed by injection collision two or more times.
本願発明により粉砕された粉砕粒は、公知の方法例えば
、昇温せしめて媒体を除去するか、または昇温せしめて
媒体と混和性を有し、かつ薬物を溶解しない別の溶媒を
加えて洗浄除するかによって媒体と結晶に分離され、回
収される。The pulverized granules pulverized according to the present invention can be washed by a known method, for example, by raising the temperature to remove the medium, or by raising the temperature and adding another solvent that is miscible with the medium and does not dissolve the drug. The medium and crystals are separated and recovered.
次に、第1図乃至第10図に基いて、本発明を実施する
に好適な装置例について説明する。Next, an example of a device suitable for carrying out the present invention will be explained based on FIGS. 1 to 10.
第1図は、本発明を実施するに好適な装置の概略図であ
り、第1図中、全体的に50で示すのは、後で詳述する
微凍結粒製造装置であり、ここで結晶含有懸濁液は、好
ましくは50(Hクロン以下の微凍結粒に製造される。FIG. 1 is a schematic diagram of an apparatus suitable for carrying out the present invention. In FIG. The containing suspension is preferably made into micro-frozen grains of less than 50 (H chrome).
該微凍結粒はりフタ−60を介して吸引されたスクリー
ン状のベルトを有するベルトコンベア70に排出され、
ストッカー80に貯蔵される。該ストッカー80は、そ
の底部に管81が接続されており、液管81から該スト
ッカー80内の微凍結粒を浮遊させるための低温の窒素
ガスまたは空気が供給されている。該ストッカー80内
の微凍結粒は管82を介して回収ボックス90の上部に
設けられた噴射装置91の側部人口に導かれる。該噴射
装置91の中央人口には微凍結粒を加速して硬質板92
に噴射せしめるための低温の窒素ガス又は空気が管93
を介して供給されている。噴射装置91のノズル端から
の噴射位置と硬質板との距1雅りは微凍結粒の形状及び
大きさによって適宜選択可能であるが、通常、10mm
〜100mmの間に設定される。このようにして噴射装
置91から噴射された微凍結粒は硬質板92に衝突し粉
砕される。尚、硬質板92の材質は、微凍結粒の硬さ及
び噴射速度に応じて適宜選択可能であるが、セラミック
板が好ましく用いられる。The finely frozen particles are sucked through the beam lid 60 and discharged to a belt conveyor 70 having a screen-like belt,
It is stored in the stocker 80. A pipe 81 is connected to the bottom of the stocker 80, and low-temperature nitrogen gas or air is supplied from the liquid pipe 81 to suspend the slightly frozen particles in the stocker 80. The finely frozen particles in the stocker 80 are led through a pipe 82 to a side port of an injection device 91 provided at the top of a collection box 90. The central part of the injection device 91 has a hard plate 92 for accelerating the finely frozen particles.
Low-temperature nitrogen gas or air is injected into the tube 93.
Supplied via. The distance between the injection position from the nozzle end of the injection device 91 and the hard plate can be selected as appropriate depending on the shape and size of the finely frozen particles, but is usually 10 mm.
It is set between ~100mm. The finely frozen particles injected from the injection device 91 in this manner collide with the hard plate 92 and are crushed. The material of the hard plate 92 can be selected as appropriate depending on the hardness of the finely frozen particles and the injection speed, but a ceramic plate is preferably used.
回収された微凍結粒は、公知の選別方法により溶媒と結
晶とに分離される。The recovered finely frozen particles are separated into a solvent and crystals by a known sorting method.
次に、第1図の微凍結粒製造装置50について詳細に説
明する。Next, the microfrozen grain manufacturing apparatus 50 shown in FIG. 1 will be explained in detail.
第2図は、第1図中の微凍結粒製造装置50のフローシ
ートであり、図に於いて1は冷媒液の貯溜容器、2は容
器内に収容した冷媒液、3は冷媒液の表層部に運動エネ
ルギーを与え、液面に漣を発生させるための種発生装置
、4は気体と結晶含有懸濁液とを混合し且つこれを微粒
化するための噴霧装置、5は冷媒液面の制御装置、60
は微凍結粒の搬出装置、7は凍結させる結晶含有懸濁液
とこれに混合する気体との冷却装置、8は冷媒液の供給
装置、9は結晶含有懸濁液の供給装置、10は混合用気
体の供給装置である。FIG. 2 is a flow sheet of the micro-frozen grain manufacturing apparatus 50 shown in FIG. 4 is a seed generator for applying kinetic energy to the refrigerant liquid surface and generating ripples on the liquid surface; 4 is a spraying device for mixing the gas and the crystal-containing suspension and atomizing it; 5 is a seed generator for generating ripples on the liquid surface of the refrigerant; control device, 60
7 is a cooling device for the crystal-containing suspension to be frozen and the gas mixed therein; 8 is a refrigerant liquid supply device; 9 is a supply device for the crystal-containing suspension; 10 is a mixing device This is a gas supply device.
前記冷媒液貯溜容器1はステンレス鋼(SUS304)
製の角胴形容器であり、下方部は逆四角錘状に形成され
ている。容器1は横幅400mm、縦幅400mm、全
高1200mmあ外形寸法を有しており、容器外壁面に
は真空断熱(図示省略)が施されている。The refrigerant liquid storage container 1 is made of stainless steel (SUS304)
It is a rectangular body-shaped container made of aluminum, with the lower part shaped like an inverted square pyramid. The container 1 has external dimensions of 400 mm in width, 400 mm in length, and 1200 mm in total height, and the outer wall of the container is provided with vacuum insulation (not shown).
冷媒液貯溜容器1内には、冷媒液供給装置8から冷媒液
供給管11を通して供給された液体窒素が冷媒液2とし
て貯溜されており、その液面りは容器底部より約500
mmの高さに設定保持されている。In the refrigerant liquid storage container 1, liquid nitrogen supplied from the refrigerant liquid supply device 8 through the refrigerant liquid supply pipe 11 is stored as the refrigerant liquid 2, and the liquid level is about 500 m above the bottom of the container.
The height is set and maintained at mm.
尚、冷媒液面りの制御は液面検知器5a、液面制御盤5
b及び制御弁5C等より構成した液面制御装置5によっ
て行なわれており、所定の設定液面高さに常時保持され
ている。The refrigerant liquid level is controlled by a liquid level detector 5a and a liquid level control panel 5.
This is carried out by a liquid level control device 5 comprising a control valve 5C and a control valve 5C, and the liquid level is always maintained at a predetermined set level.
前記種発生装置3は本発明において好ましく用いられる
粒径500ミクロン以下の水球を作るために用いられ、
冷媒液に運動エネルギーを与えて液面に漣を発生させる
ものであり、散気管3a、散気調整弁3b、流量計3C
等より構成されている。The seed generator 3 is used to produce water spheres with a particle size of 500 microns or less, which is preferably used in the present invention,
It gives kinetic energy to the refrigerant liquid to generate ripples on the liquid surface, and includes an aeration pipe 3a, an aeration adjustment valve 3b, and a flow meter 3C.
It is composed of etc.
散気管3aは、第3図及び第4図に示す如く、四角形に
形成されており、液面下40〜150m+mの位置に水
平に配設されている。尚、散気管3aの深さが深すぎる
と、ガスが冷却されて後述する如き気泡流による作用効
果が減少すると共に、冷媒液並びに散気用ガス(冷媒ガ
ス)の消費量が増大する。従って、散気管3aの深さは
100mII1以内が望ましい。As shown in FIGS. 3 and 4, the diffuser pipe 3a is formed in a rectangular shape and is horizontally disposed at a position of 40 to 150 m+m below the liquid level. Note that if the depth of the aeration tube 3a is too deep, the gas will be cooled and the effect of the bubble flow as described later will be reduced, and the consumption of the refrigerant liquid and the aeration gas (refrigerant gas) will increase. Therefore, the depth of the diffuser pipe 3a is preferably within 100 mII1.
散気管3aには50〜100mmピッチでガス噴出孔3
dが、中央部へ向けて略水平に開孔されており、第2図
に示す冷媒液供給装置8の気相部から冷媒ガス供給管1
2、調整弁3bを通して冷媒ガスが供給され、冷媒液内
へ噴出されている。Gas ejection holes 3 are provided in the diffuser pipe 3a at a pitch of 50 to 100 mm.
d is opened substantially horizontally toward the center, and is connected to the refrigerant gas supply pipe 1 from the gas phase part of the refrigerant liquid supply device 8 shown in FIG.
2. Refrigerant gas is supplied through the regulating valve 3b and is ejected into the refrigerant liquid.
前記、散気管3aからの冷媒ガスの噴出流量は、200
〜400n/m2.min位いが最適であり、これによ
り、第6図に示す如く冷媒液の表層部に気泡13の上昇
流が生じると共に、上昇した気泡13は液面近傍に於い
て破裂する。これ等の気泡流によって冷媒液゛表層部に
与えられる運動エネルギーにより、冷媒液表面に波高が
5〜20mmの漣Wが発生すると共に、後述する如く冷
媒液内へ落下して連結した連結枝■が揺動され、凍結粒
同士の固着が防止される。The flow rate of the refrigerant gas ejected from the diffuser pipe 3a is 200
~400n/m2. The optimal value is about 100 min, and as a result, as shown in FIG. 6, an upward flow of bubbles 13 is generated in the surface layer of the refrigerant liquid, and the bubbles 13 that have risen burst near the liquid surface. The kinetic energy imparted to the surface layer of the refrigerant liquid by these bubble flows generates ripples W with a wave height of 5 to 20 mm on the surface of the refrigerant liquid, and as will be described later, connecting branches that fall into the refrigerant liquid and are connected. is swung to prevent frozen particles from sticking to each other.
又、気泡流の存在により、冷媒液表層部の液密度が低下
することになり、凍結粒との密度差が増加して、その沈
降が促進されることになる。Furthermore, the presence of bubble flow reduces the liquid density at the surface layer of the refrigerant liquid, increasing the density difference between the refrigerant and the frozen particles, and promoting its settling.
尚、前記漣の波高は、5〜1(bnm程度が最適であり
、波高が20mm以上になると、逆に冷媒液表層部の攪
拌作用によって凍結粒の沈降が阻害されることになる。The wave height of the ripples is optimally about 5 to 1 (bnm); if the wave height is 20 mm or more, the settling of frozen particles will be inhibited by the stirring action of the surface layer of the refrigerant liquid.
また、第2図に示す如く種発生装置3として散気管3a
を使用し、冷媒液供給装置8の気相部から冷媒ガスを供
給するようにしているが、冷媒ガスの貯蔵設備を別途に
設け、ここから散気管3aへ冷媒ガスを供給するように
してもよい。又、露点の低いガスやCO2を含有するガ
ス以外であれば、冷媒ガスに代えて例えば脱CO2処理
を施した空気等を使用することも可能である。In addition, as shown in FIG. 2, an aeration pipe 3a is used as a seed generator 3.
is used to supply the refrigerant gas from the gas phase part of the refrigerant liquid supply device 8, but it is also possible to provide a separate refrigerant gas storage facility and supply the refrigerant gas from there to the diffuser pipe 3a. good. Furthermore, as long as the gas has a low dew point or a gas containing CO2, it is also possible to use, for example, air that has been subjected to CO2 removal treatment instead of the refrigerant gas.
前記種発生装置3としては、この池に、下記の如き構成
の装置の使用が可能である。As the seed generator 3, a device having the following configuration can be used in this pond.
(a) 散液管型発生装置
冷媒液の液面下に、小孔を形成した吸液管を配設し、該
吸液管より冷媒液供給装置8からの冷媒液を噴出する。(a) Sprinkle tube type generator A liquid suction pipe with small holes is provided below the surface of the refrigerant liquid, and the refrigerant liquid from the refrigerant liquid supply device 8 is spouted from the liquid suction pipe.
尚、この場合には、第1図に於ける冷媒液供給管11は
不要となり、これに替えて冷媒液戻り管を設け、冷媒液
面を一定に保持するようにする。In this case, the refrigerant liquid supply pipe 11 shown in FIG. 1 becomes unnecessary, and a refrigerant liquid return pipe is provided in its place to maintain a constant refrigerant liquid level.
(b) 発振子型漣発生装置
第5図11及び第5図11に示す如く、冷媒液貯溜容器
1の内部に、一定の速度で揺動、往復動若しくは回転運
動をする発振子20を配設し、容器1の外部に設置した
モータ21等により前記発振子を作動させ、冷媒液2に
機械的な振動エネルギーを与えて冷媒液面しに漣を発生
させる。(b) Oscillator type ripple generator As shown in FIG. 5 and FIG. The oscillator is operated by a motor 21 or the like installed outside the container 1, and mechanical vibrational energy is applied to the refrigerant liquid 2 to generate ripples on the refrigerant liquid surface.
(C) 振動子型漣発生装置
第5図11に示す如く、冷媒液貯溜容器1の外部又は内
部に所望の周波数の振動力を発する音波振動子22を設
け、振動子を介して音波エネルギーを冷媒液2に与えて
、冷媒液面しに漣を発生させる。(C) Vibrator-type ripple generator 5 As shown in FIG. 11, a sonic vibrator 22 that emits a vibration force of a desired frequency is provided outside or inside the refrigerant liquid storage container 1, and sonic energy is transmitted through the vibrator. It is applied to the refrigerant liquid 2 to generate ripples on the refrigerant liquid surface.
ω)噴射型環発生装置
冷媒液面上に噴射管を配設し、該噴射管より冷媒ガス、
脱CO□処理をした空気等の露点の比較的高いガスや冷
媒液等を液面へ向けて噴射し、冷媒液に運動エネルギー
を与えてその液面に漣を発生させる。ω) Injection type ring generator An injection pipe is arranged above the refrigerant liquid surface, and the refrigerant gas,
A gas with a relatively high dew point, such as air that has been subjected to CO□ removal, or a refrigerant liquid is injected toward the liquid surface, giving kinetic energy to the refrigerant liquid and generating ripples on the liquid surface.
(e) 震盪形漣発生装置
第5図11に示す如く冷媒液貯溜容器1を震動台22等
の上に設置し、貯溜容器1自体にカム23及びスプリン
グ24等を介して機械的な震盪力を与えることによって
容器内部の冷媒液2に震盪作用を与え、液面りに漣を発
生させる。(e) Concussion type ripple generator As shown in FIG. By applying this, a shaking action is applied to the refrigerant liquid 2 inside the container, and ripples are generated on the liquid surface.
前記噴霧装置4は、凍結粒にするべき凍結原液と気体と
を混合し、該気液混合体内の凍結原液を500ミクロン
以下の液滴とするものである。第7図はその一例を示す
ものであり、本体4aの後方に液入口4bと気体人口4
Cが形成されており、両通路4b’と4c′とを合体せ
しめてスロート部4dを構成し、ここで液体と気体とが
混合される。スロート部4dを出た気液混合体は、更に
混合室4e内へ導かれ、ここで案内羽根4fにより攪拌
並びに分散された後、ノズル孔4gから噴出される。The spraying device 4 mixes the frozen stock solution to be made into frozen particles with gas, and converts the frozen stock solution in the gas-liquid mixture into droplets of 500 microns or less. FIG. 7 shows an example, in which a liquid inlet 4b and a gas inlet 4 are provided at the rear of the main body 4a.
C is formed, and both passages 4b' and 4c' are combined to form a throat portion 4d, where liquid and gas are mixed. The gas-liquid mixture exiting the throat portion 4d is further guided into the mixing chamber 4e, where it is stirred and dispersed by the guide vanes 4f, and then jetted out from the nozzle hole 4g.
尚、噴霧装置4としては、気液の混合機構と気液混合体
を微粒化して噴出する機構とを備えたものであれば、如
何なる構造や形態のものであってもよいことは勿論であ
る。It goes without saying that the spray device 4 may have any structure or form as long as it is equipped with a gas-liquid mixing mechanism and a mechanism that atomizes and sprays the gas-liquid mixture. .
当該噴霧装置4の液入口4bへは、微凍結粒にすべき結
晶含有懸濁液が第2図に示した結晶含有懸濁液供給装置
9からポンプ14、減圧弁15、制御弁16及び後述す
る冷却装置7等を介して供給されており、その供給圧は
1.0〜2.0 kg / cd gに選定されている
。又、噴霧装置4の気体人口4Cへは、混合用気体供給
装置10から液体に比較的溶は難い気体が減圧弁17、
流量計18、制御弁19、冷却装置7を通して、1.0
〜2.0 kg /Cイgの加圧力でもって供給されて
いる。The crystal-containing suspension to be made into finely frozen particles is supplied to the liquid inlet 4b of the spray device 4 from the crystal-containing suspension supply device 9 shown in FIG. It is supplied through a cooling device 7 etc., and the supply pressure is selected to be 1.0 to 2.0 kg/cd g. Further, gas that is relatively difficult to dissolve in liquid is supplied to the gas population 4C of the spray device 4 from the mixing gas supply device 10 through the pressure reducing valve 17,
1.0 through the flow meter 18, control valve 19, and cooling device 7
It is supplied with a pressing force of ~2.0 kg/Cig.
又、第2図の装置では混合用気体供給装置10を別に設
けているが、冷媒液供給装置8の気相部から混合用気体
を噴霧袋W4へ供給する様にしてもよい。Further, in the apparatus shown in FIG. 2, the mixing gas supply device 10 is provided separately, but the mixing gas may be supplied from the gas phase portion of the refrigerant liquid supply device 8 to the spray bag W4.
前記結晶含有懸濁液と気体との混合比(液体b/H+気
体Nj7/m1n)は0.5〜1.5に選定するのが最
適であり、混合比を変更することにより、気液供給圧が
一定の場合でも、凍結粒の粒径を最少1/10の径まで
小さくすることができる。The mixing ratio of the crystal-containing suspension and gas (liquid b/H + gas Nj7/m1n) is optimally selected to be 0.5 to 1.5, and by changing the mixing ratio, gas-liquid supply can be controlled. Even when the pressure is constant, the particle size of the frozen particles can be reduced to at least 1/10 of the diameter.
又、ノズル孔4gの径は小さいほど好都合であるが、加
工の困難性や詰まりの発生等の問題があるため、0,3
〜L Om+++φ程度の径が望ましい。In addition, the smaller the diameter of the nozzle hole 4g, the better, but since there are problems such as difficulty in machining and occurrence of clogging,
A diameter of approximately ˜L Om+++φ is desirable.
前記噴霧装置4のスロート部4d及び混合室4e内で形
成された気液混合体は、案内羽根4fによって外周方向
へ均等に分散され、ノズル4gより上方より冷媒液面へ
向けて噴出される。この時、混合された気体は、ノズル
4gを通過する際に微粒化された液体微粒の内部と、液
体微粒相互の間に介在することになり、液体微粒内に含
まれた気体は膨張して液体微粒を更に分割して細分化し
、これを飛散せしめる。又、液体微粒相互間に介在する
気泡は液体微粒をより強力に飛散せしめることになり、
飛散時の微粒相互の衝突により、これを更に細微粒にす
る作用をする。The gas-liquid mixture formed in the throat portion 4d and mixing chamber 4e of the spray device 4 is evenly distributed in the outer circumferential direction by the guide vanes 4f, and is ejected from above from the nozzle 4g toward the refrigerant liquid surface. At this time, when the mixed gas passes through the nozzle 4g, it will be present inside the atomized liquid particles and between the liquid particles, and the gas contained in the liquid particles will expand. The liquid particles are further divided into fine particles, which are then dispersed. In addition, the air bubbles interposed between the liquid particles will cause the liquid particles to scatter more strongly.
Collision between fine particles during scattering acts to make them even finer particles.
一方、噴霧装置4から噴出された液体微粒は、容器1内
を落下中に表面張力によって球形となり、冷媒液面上へ
落下する。而して、噴霧装置4から冷媒液面までの落下
距離及び容器空間部の温度は、凍結微粒の粒径並びに形
態に大きな影響を及ぼすものであり、落下距離を500
〜1500mm、容器空間部温度を一15℃以下とすれ
ばよいが、−20℃以下とするのが望ましいことが、実
験により確S忍されている。On the other hand, the liquid particles ejected from the spray device 4 become spherical due to surface tension while falling within the container 1, and fall onto the refrigerant liquid surface. Therefore, the falling distance from the spray device 4 to the refrigerant liquid level and the temperature of the container space have a large influence on the particle size and morphology of the frozen fine particles, and the falling distance is
~1500 mm, the temperature of the container space may be kept at -15°C or less, but experiments have shown that it is desirable to keep it at -20°C or less.
前記冷媒液面制御装置5は、液面りと噴霧装置4間の距
離を略一定に保持する機能を果し、公知の液面検知器5
a、液面制御器5b及び冷媒液供給管11に介設した制
御弁5C等より構成されている。The refrigerant liquid level control device 5 has the function of keeping the distance between the liquid level and the spray device 4 substantially constant, and uses a known liquid level detector 5.
a, a liquid level controller 5b, a control valve 5C interposed in the refrigerant liquid supply pipe 11, and the like.
尚、冷媒液の液面は漣によって常時変動するため、液面
の制御は、漣の波高部が所定のレベル範囲内に位置する
ように制御されている。Since the liquid level of the refrigerant liquid constantly fluctuates due to ripples, the liquid level is controlled so that the crest of the ripples is located within a predetermined level range.
前記冷却装置7は、容器1内へ噴霧する凍結原液と混合
用気体の温度を下げ、冷媒液の消費量の低減を図るもの
である。該冷却装置7は液体冷却器7aと気体冷却器7
bとから構成されており、貯溜容器1内の冷媒ガスを導
入して液体並びに気体の冷却を行なう構成としている。The cooling device 7 lowers the temperature of the frozen stock solution and the mixing gas that are sprayed into the container 1, thereby reducing the amount of refrigerant liquid consumed. The cooling device 7 includes a liquid cooler 7a and a gas cooler 7.
b, and the refrigerant gas in the storage container 1 is introduced to cool the liquid and gas.
尚、第2図の装置に於いては、液体及び気体を夫々個別
的に冷却し、冷却後に噴霧装置4により、混合・微粒化
する構成としているが、気液混合部と微粒化部とを分離
し、先きに気液混合を行なってから、次に該混合体を冷
却し、その後これを微粒化する構成としてもよい。In the apparatus shown in FIG. 2, the liquid and gas are individually cooled, and after cooling, they are mixed and atomized by the spray device 4, but the gas-liquid mixing section and the atomization section are A configuration may also be adopted in which the mixture is separated, first mixed with gas and liquid, and then the mixture is cooled and then atomized.
噴霧装置4から噴出された凍結原液の微粒には冷媒液面
上へ落下して凍結並びに硬化され、前記冷媒液面上の漣
の作用により、凍結微粒子同志が固着して皮膜状になる
のが防止され、独立した状態で順次沈降する。容器底部
へ沈降した凍結微粒は、装置50の底部に接続された管
を介して搬出装置60により外部へ搬出されて行く。The fine particles of the frozen stock solution ejected from the spray device 4 fall onto the refrigerant liquid surface and are frozen and hardened, and due to the action of the ripples on the refrigerant liquid surface, the frozen fine particles stick together and form a film. prevented and separate sequential sedimentation. The frozen fine particles that have settled to the bottom of the container are transported to the outside by a transport device 60 via a pipe connected to the bottom of the device 50.
搬出装置60は、空気輸送式のりフタ−60であり、装
置50から搬出した微凍結粒をコンベアー70へ供給す
る。尚、+i出装置として第2図の装置では、上記のよ
うな空気輸送式のりフタ−60を用いたが、第8図に示
す如く容器1内へ挿入したガイドバイブロaと、ガイド
パイプ内に回転自在に配設したスクリュー回転体6bと
、駆動用モークロC等から構成されたスクリューコンベ
ア式の11出装置としてもよいし、ベルトコンベア式の
搬出装置やその他の形式の搬送装置、例えば前記の微凍
結粒製造装置内から、その装置容器外へ微凍結粒取出管
を開口し、その取出管の装置内下端部にて気泡を伴った
上昇流を発生させて、この上昇流とともに製造した微凍
結粒を取出管により容器外に冷媒とともに取出し、冷媒
と微凍結粒とを分離してなる搬送袋@(昭和61年7月
23日出願口、発明の名称「凍結粒取出し装置」の特願
昭61−173317号明細書参照)であってもよいこ
とは勿論である。The carry-out device 60 is a pneumatic transport type lid 60 and supplies the finely frozen particles carried out from the device 50 to a conveyor 70. In the device shown in FIG. 2, the above-mentioned pneumatic glue lid 60 was used as the +i release device, but as shown in FIG. It may be a screw conveyor type 11 output device consisting of a rotatably arranged screw rotating body 6b and a drive mokro C, etc., or a belt conveyor type unloading device or other type of conveyance device, such as the above-mentioned conveyance device. A microfrozen grain extraction pipe is opened from inside the microfrozen grain manufacturing equipment to the outside of the equipment container, and an upward flow accompanied by air bubbles is generated at the lower end of the extraction pipe inside the equipment, and the produced microfrozen grains are removed along with this upward flow. The frozen grains are taken out of the container together with the refrigerant through a take-out pipe, and the refrigerant and the finely frozen grains are separated into a transport bag (filed on July 23, 1985, patent application with the title of the invention: "Frozen grain removal device") Of course, it may also be used (see the specification of Sho 61-173317).
次いで、本発明の実施例を挙げるが、本発明は何んらこ
れらによって限定されるものではない。Next, examples of the present invention will be given, but the present invention is not limited by these in any way.
実施例
次に、本発明の結晶の凍結微粉砕法の実施例について説
明する。EXAMPLE Next, an example of the method of freezing and pulverizing crystals of the present invention will be described.
実施例1
150gのセファレキシンを室温で1000mβの水に
懸濁し、これに濃塩酸を滴下してセファレキシンを溶解
せしめた( p H1,8〜1.9)。Example 1 150 g of cephalexin was suspended in 1000 mβ water at room temperature, and concentrated hydrochloric acid was added dropwise to dissolve the cephalexin (pH 1.8 to 1.9).
次いでこれを55℃に加熱した後濃アンモニア水溶液を
攪拌下加えてp H4,3とした。その後沈澱したセフ
ァレキシン1永和物の柱状結晶(30〜50ミクロン径
)濾取し、さらに少量の水で洗浄し、乾燥した。Then, after heating the mixture to 55° C., a concentrated aqueous ammonia solution was added under stirring to adjust the pH to 4.3. Thereafter, the precipitated columnar crystals (diameter of 30 to 50 microns) of cephalexin 1 were collected by filtration, further washed with a small amount of water, and dried.
このセファレキシン1永和物結晶をクロロホルムに分散
せしめて0.1 g / m lのセファレキシン懸濁
液を調製した。そして、前述の第1図の装置を用いて実
験を行った。該装置中、冷媒液貯溜器1として、1折面
が400mmx 400mm。The cephalexin 1 permanent crystals were dispersed in chloroform to prepare a 0.1 g/ml cephalexin suspension. Then, an experiment was conducted using the apparatus shown in FIG. 1 described above. In this device, the refrigerant liquid reservoir 1 has a single folded surface of 400 mm x 400 mm.
四角胴部の高さが、900mmであり、その下方に高さ
300mmの逆四角錘部を備えた形態の容器を形成し、
冷媒液2として液体窒素を容器底より500mmの高さ
にまで入れた。即ち、容器天井より冷媒液面りまでの距
離を700mmとした。Forming a container in which the height of the square body is 900 mm and an inverted square pyramid part with a height of 300 mm is provided below the body,
Liquid nitrogen was poured as the refrigerant liquid 2 to a height of 500 mm from the bottom of the container. That is, the distance from the container ceiling to the refrigerant liquid level was 700 mm.
又、液面下50市の位五に四角状の散気管(350mm
X 350++un)を水平に配設し、該散気管から容
器中心部に向けて、液体窒素供給タンクの気相部からの
窒素ガスを300β/m′。In addition, a square air diffuser (350 mm
X 350++un) was installed horizontally, and nitrogen gas from the gas phase of the liquid nitrogen supply tank was supplied at a rate of 300β/m' from the diffuser pipe toward the center of the container.
minの割合で供給し、液体窒素の外表面に波高の平均
値が8mmの漣を発生させた。Ripples with an average wave height of 8 mm were generated on the outer surface of the liquid nitrogen.
一方、凍結原液を上記セファレキシン懸濁液、混合用気
体を高圧容器内に貯溜した窒素ガス(25℃)として、
該懸濁液を0.2j’/minの流量、および窒素ガス
をlj!/minの流量にて両者を混合し、0.5 m
mφのノズル孔を有する噴霧装置(液体窒素の液面りよ
り約700mm上方に配設されている)から、混合後の
スプレー圧2〜2.5kg/aI11にて混合流体を液
面へ向けて噴霧した。また、この時の容器内上部空間の
最高温度は一20℃であった。On the other hand, the frozen stock solution was the above cephalexin suspension, and the mixing gas was nitrogen gas (25°C) stored in a high-pressure container.
The suspension was supplied at a flow rate of 0.2j'/min and nitrogen gas at lj! Mix both at a flow rate of 0.5 m/min.
From a spray device (located approximately 700 mm above the liquid nitrogen level) having a nozzle hole of mφ, the mixed fluid is directed toward the liquid surface at a spray pressure of 2 to 2.5 kg/aI11 after mixing. Sprayed. Further, the maximum temperature in the upper space inside the container at this time was -20°C.
更に、容器内の液体窒素の液面を一定に保持するために
、容器内へ供給した液体窒素の流量は2OR/Hであり
、且つ冷却装置により水及び混合用窒素ガスを冷却した
後の排出窒素ガス(即ち容器内から導出した気化ガス)
は20×0.65Nm’/Hrであった。Furthermore, in order to maintain a constant level of liquid nitrogen in the container, the flow rate of liquid nitrogen supplied into the container is 2OR/H, and the water and nitrogen gas for mixing are cooled by a cooling device before being discharged. Nitrogen gas (i.e. vaporized gas extracted from inside the container)
was 20×0.65 Nm'/Hr.
前述の如き条件下において、約10分間混合流体くセフ
ァレキシン懸濁液十窒素)を連続的に噴射したとき、約
1リツトルのさらさらしたセファレキシン結晶含有水球
が得られ、その平均粒径は200〜300ミクロンであ
った。Under the conditions described above, when the mixed fluid (cephalexin suspension 10 nitrogen) was continuously injected for about 10 minutes, about 1 liter of free-flowing water spheres containing cephalexin crystals were obtained, and the average particle size was 200 to 300. It was a micron.
この水球は、リフクーロ0.コンベア70によって底部
から水球を浮遊させるために圧力2kg / ciの一
85℃の窒素ガスが送られたストッカーに貯蔵されて品
温−85℃に水球を保持し、次いで8.3 n+m径の
ノズルを有する噴射装置91から噴射された。このとき
、噴射装置91の中央入口から供給される加速用の窒素
ガスは、加速圧力4゜7〜5 kg / cffl 、
温度−85℃であり、水球のノズルからの噴射時の温度
は一85℃であった。以上の条件下で、噴射距離りを2
0mmに設定して水球の噴射を行った。This water polo is 0. The water balls were stored in a stocker to which nitrogen gas at a pressure of 2 kg/ci and 85°C was fed to suspend the water balls from the bottom by a conveyor 70 to maintain the water balls at a temperature of -85°C, and then a nozzle with a diameter of 8.3 n+m It was injected from an injector 91 having a. At this time, the nitrogen gas for acceleration supplied from the central inlet of the injection device 91 has an acceleration pressure of 4°7 to 5 kg/cffl,
The temperature was -85°C, and the temperature at the time of injection from the water sphere nozzle was -85°C. Under the above conditions, the injection distance is 2
The water ball was jetted with the setting set to 0 mm.
次いで破砕された粒を回収した。The crushed grains were then collected.
クロロホルムを用いた場合においては、破砕された粒を
65℃の恒温槽に入れてクロロホルムを蒸発除去せしめ
て10〜20ミクロンに破砕されたセファレキシン1永
和物結晶破砕物を得た。In the case of using chloroform, the crushed grains were placed in a constant temperature bath at 65°C to evaporate and remove the chloroform to obtain crushed crystals of cephalexin 1 hydrate crushed into 10 to 20 micron particles.
実施例2
再結晶化手段により得られたテオフィリン結晶を水に分
散して0.1g/ml懸濁液を調製した。この懸濁液を
用い、以下実施例1と同じ装置を用いて、テオフィリン
結晶含有氷粒(粒径200〜300ミクロン)を得、さ
らに同一条件にて噴射して破砕された粒を回収した。次
いで常温にて濾取後乾燥器に入れテオフィリン結晶破砕
物(10〜20ミクロン)を得た。Example 2 Theophylline crystals obtained by recrystallization were dispersed in water to prepare a 0.1 g/ml suspension. Using this suspension, theophylline crystal-containing ice grains (particle size 200 to 300 microns) were obtained using the same apparatus as in Example 1, and the crushed grains were collected by spraying under the same conditions. Then, it was filtered at room temperature and placed in a dryer to obtain crushed theophylline crystals (10 to 20 microns).
実施例3
再結晶化手段により得られたナリジクス酸結晶を水に分
散して0.05g/m!懸濁液を調製した。Example 3 The nalidixic acid crystals obtained by the recrystallization method were dispersed in water to give a dispersion of 0.05 g/m! A suspension was prepared.
この懸濁液を用いて、以下実施例1と同じ装置を用いて
ナリジクス酸結晶含有氷粒(粒径200〜300ミクロ
ン)を得、さらに同一条件にて噴射(なお、噴射距離り
を50m+mに設定した)して破砕された粒を回収した
。次いで常温にて濾取後乾燥器に入れナリジクス酸結晶
破砕物(15〜25ミクロン)を得た。Using this suspension, ice grains containing nalidixic acid crystals (particle size 200 to 300 microns) were obtained using the same apparatus as in Example 1, and further jetted under the same conditions (the jetting distance was set to 50 m + m). The crushed grains were collected. The mixture was then filtered at room temperature and placed in a dryer to obtain crushed nalidixic acid crystals (15 to 25 microns).
実施例4
セフアレキシン1永和物粒状結晶(30〜50ミクロン
径)をクロロホルムに分散せしめて、0.05g/mA
のセファレキシン懸濁液を調製した。Example 4 Cephalexin 1 permanent granular crystals (30 to 50 micron diameter) were dispersed in chloroform, and 0.05 g/mA
A suspension of cephalexin was prepared.
次いで実施例1と同一の装置を用いて、セファレキシン
懸濁液を0.2A’/minの流量、窒素ガスを1β/
minの流量、ノズル孔0.7 n+mφ、スプレー圧
4 kg / ciの条件にて氷粒を調製した。この結
果得られた氷粒は50〜100ミクロン径であった。Next, using the same apparatus as in Example 1, the cephalexin suspension was heated at a flow rate of 0.2 A'/min, and the nitrogen gas was heated at a flow rate of 1β/min.
Ice grains were prepared under the following conditions: a flow rate of min, a nozzle hole of 0.7 n+mφ, and a spray pressure of 4 kg/ci. The resulting ice particles had a diameter of 50 to 100 microns.
さらに、この氷粒を実施例1と同一条件にて噴射して破
砕された粒を回収した。次いで65℃恒温槽に破砕粒を
入れてクロロホルム分を除去し、5〜20ミクロンに破
砕されたセファレキシン1水和物結晶破砕物を得た。Furthermore, the ice particles were injected under the same conditions as in Example 1, and the crushed ice particles were collected. The crushed grains were then placed in a 65° C. constant temperature bath to remove the chloroform content to obtain crushed cephalexin monohydrate crystals crushed into 5-20 micron particles.
発明の効果
本発明によれば、連続的に結晶を微粉砕することが可能
となり、多品種の結晶を容易に微粉砕することが可能と
なる。また、ボールミル等による粉砕に見られたような
異物の混入もなく、純粋な微結晶が回収でき、粉砕中に
熱も発生しない新規な粉砕方法が提供される。Effects of the Invention According to the present invention, it becomes possible to continuously pulverize crystals, and it becomes possible to easily pulverize a wide variety of crystals. Furthermore, a novel pulverization method is provided in which pure microcrystals can be recovered without the contamination of foreign substances as seen in pulverization using a ball mill or the like, and no heat is generated during the pulverization.
第1図は本発明の実施に好適な装置の概略図である。
第2図は第1図中の微凍結粒製造装置のフローシートで
ある。
第3図は第2図の装置の散気管3aの配置状態を示す平
面図であり、第4図はその側面図である。
第5図11.第5図11.第5図11及び第5図11は
、第3図の散気管3aに代替可能な線発生装置の具体例
を示すものである。
第6図は第3図の散気管からの気泡粒の作用説明図であ
る。
第7図は第2図の装置の噴霧装置4の一例を示す縦断面
図である。
第8図は第2図の装置の微凍結粒の搬出装置6の一例を
示す断面図である。
第9図は2以上の噴射装置による概略図である。
第10図11は、噴射後の試料回収装置の全体概略図で
あり、第10図11は、第10図11の装置の側断面図
である。
尚、図面中、
■ 微凍結粒 K 凍結原液の微粒L 冷媒液
面 W 漣
1 冷媒液貯溜容器 2 冷媒液
3 線発生装置 4 噴霧装置
5 冷媒液面制御装置 6 凍結微粒搬出装置7 冷却
装置 8 冷媒液供給装置9 凍結原液供給装
置 10 混合用気体供給装置11 冷媒液供給管
12 冷媒ガス供給管13 気泡
50 微凍結粒製造装置60 リフター
70 ベルトコンベア80 ストッカー
91 ノズル92 硬質板
である。
代理人 三宅正夫 他1名
第 3 図
第 5 図(A)
第 5 図(B)
手 阜売 ネ市 正 書(方式)
昭和61年12月4日
特許庁長官 黒 1)明 雄 殿
1 事件の表示
昭和61年特許願第220715号
2 発明の名称
結晶の凍結微粉砕法
3 補正をする者
事件との関係 特許出願人
名称 株式会社 不二精機製造所 (他2名)4
代理人 〒100
5 補正命令の日付 昭和61年11月5日6 補正
により増加する発明の数 0
7 補正の対象
明細書の「図面の簡単な説明」及び「発明の詳細な説明
」の各欄
(1)明細書第31頁第17行の「第5図比第5図11
、第5図11及び第5図II、」を「第5図(A)、第
5図(B)、第5図(C)及び第5図(D) 、 」と
訂正する。
(2)同第32頁第7行の「第10図11Jを「第10
図(A)」と訂正する。
(3)同第32頁第8行のrt510図11は、第10
図11装置の」を「第10図(B)は、第10図(A)
の装置の」と訂正する。
(4)同第19頁第9行の「第5図11及び第5図11
に示す如く」を「第5図(A)及び第5図(B)に示す
如く」と訂正する。
(5)同第19頁第17行の「第5図IIに示す如く」
を「第5図(C)に示す如く」と訂正する。
(6)同第20頁第9行の「第5図11に示す如く」を
「第5図(D)に示す如く」と訂正する。FIG. 1 is a schematic diagram of an apparatus suitable for carrying out the invention. FIG. 2 is a flow sheet of the microfrozen grain manufacturing apparatus in FIG. 1. 3 is a plan view showing the arrangement of the air diffuser 3a of the apparatus shown in FIG. 2, and FIG. 4 is a side view thereof. Figure 5 11. Figure 5 11. FIGS. 5 and 11 show a specific example of a line generating device that can be substituted for the air diffuser 3a in FIG. 3. FIG. 6 is an explanatory diagram of the action of the air bubbles from the air diffuser shown in FIG. 3. FIG. 7 is a longitudinal sectional view showing an example of the spray device 4 of the device shown in FIG. FIG. 8 is a sectional view showing an example of the finely frozen particle delivery device 6 of the device shown in FIG. 2. FIG. 9 is a schematic diagram with two or more injection devices. FIG. 10 is an overall schematic diagram of the sample recovery device after injection, and FIG. 10 is a side sectional view of the device shown in FIG. 10. In the drawing, ■ Finely frozen particles K Fine particles of frozen stock solution L Refrigerant liquid level W Ripple 1 Refrigerant liquid storage container 2 Refrigerant liquid 3 Line generator 4 Spraying device 5 Refrigerant liquid level control device 6 Frozen fine particles delivery device 7 Cooling device 8 Refrigerant liquid supply device 9 Frozen stock liquid supply device 10 Mixing gas supply device 11 Refrigerant liquid supply pipe 12 Refrigerant gas supply pipe 13 Bubbles
50 Microfrozen grain manufacturing device 60 Lifter
70 Belt conveyor 80 Stocker
91 Nozzle 92 This is a hard plate. Agent Masao Miyake and 1 other person Figure 3 Figure 5 (A) Figure 5 (B) Te Fuuri Neichi Seisho (Method) December 4, 1985 Commissioner of the Patent Office Kuro 1) Akio Tono 1 Case Indication of 1985 Patent Application No. 220715 2 Name of the invention Crystal freezing and pulverization method 3 Relationship with the case of the person making the amendment Name of patent applicant Fuji Seiki Seisakusho Co., Ltd. (2 others) 4
Agent 〒100 5 Date of amendment order November 5, 1985 6 Number of inventions increased by amendment 0 7 Each column of "Brief explanation of drawings" and "Detailed explanation of invention" of the specification subject to amendment (1) “Figure 5 ratio Figure 5 11” on page 31, line 17 of the specification
, FIG. 511 and FIG. 5 II," are corrected to "FIG. 5(A), FIG. 5(B), FIG. 5(C), and FIG. 5(D),". (2) "Figure 10 11J" in page 32, line 7 of the same page.
Figure (A)” is corrected. (3) The rt510 figure 11 on page 32, line 8 is the 10th
Figure 11 of the apparatus is changed to Figure 10 (B) and Figure 10 (A).
"of the device" is corrected. (4) “Figure 5 11 and Figure 5 11” on page 19, line 9 of the same
"As shown in FIG. 5(A) and FIG. 5(B)" is corrected to "as shown in FIG. 5(A) and FIG. 5(B)." (5) "As shown in Figure 5 II" on page 19, line 17.
is corrected to "as shown in FIG. 5(C)". (6) "As shown in FIG. 5 (D)" in line 9 of page 20 is corrected to "as shown in FIG. 5 (D)."
Claims (5)
に500ミクロン径以下の液滴として、該媒体の融点以
下の低温に保持した液化ガス冷媒中に投下して実質的に
粒径500ミクロン以下の薬物結晶含有微凍結粒とした
後、該薬物結晶含有微凍結粒を噴射し衝突による衝撃力
を与えて粉砕することを特徴とする薬物結晶の凍結微粉
砕法(1) Drug crystals suspended in a liquid medium are dropped together with the medium into droplets with a diameter of 500 microns or less into a liquefied gas refrigerant maintained at a low temperature below the melting point of the medium to substantially reduce the particle size to 500 microns. A method of freezing and pulverizing drug crystals, which is characterized in that the micro-frozen particles containing drug crystals are formed into submicron-sized micro-frozen particles, and then the micro-frozen particles containing drug crystals are pulverized by applying an impact force through collision.
形成された冷媒に投下される特許請求の範囲第1項に記
載の微粉砕法。(2) The pulverization method according to claim 1, wherein the drug crystals suspended in the medium are dropped into a refrigerant having ripples formed on its surface.
5g/ml含むことを特徴とする特許請求の範囲第1又
は第2項に記載の微粉砕法。(3) The medium contains the crystals at a concentration of 0.005 g/ml to 0.00 g/ml.
The pulverization method according to claim 1 or 2, characterized in that the pulverization method contains 5 g/ml.
てなる特許請求の範囲第1項に記載の微粉砕法。(4) The pulverization method according to claim 1, which comprises jetting and colliding finely frozen particles containing drug crystals against a resistor.
る特許請求の範囲第1項に記載の微粉砕法。(5) The pulverization method according to claim 1, which comprises jetting and colliding finely frozen particles containing drug crystals with each other.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22071586A JPH0638840B2 (en) | 1986-09-18 | 1986-09-18 | Freezing and pulverization of crystals |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22071586A JPH0638840B2 (en) | 1986-09-18 | 1986-09-18 | Freezing and pulverization of crystals |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6373964A true JPS6373964A (en) | 1988-04-04 |
JPH0638840B2 JPH0638840B2 (en) | 1994-05-25 |
Family
ID=16755375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP22071586A Expired - Fee Related JPH0638840B2 (en) | 1986-09-18 | 1986-09-18 | Freezing and pulverization of crystals |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0638840B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007287799A (en) * | 2006-04-13 | 2007-11-01 | Nitto Denko Corp | Wiring circuit board aggregate sheet |
-
1986
- 1986-09-18 JP JP22071586A patent/JPH0638840B2/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007287799A (en) * | 2006-04-13 | 2007-11-01 | Nitto Denko Corp | Wiring circuit board aggregate sheet |
US8017871B2 (en) | 2006-04-13 | 2011-09-13 | Nitto Denko Corporation | Wired circuit board assembly sheet |
US8362360B2 (en) | 2006-04-13 | 2013-01-29 | Nitto Denko Corporation | Wired circuit board assembly sheet |
US8487189B2 (en) | 2006-04-13 | 2013-07-16 | Nitto Denko Corporation | Wired circuit board assembly sheet |
Also Published As
Publication number | Publication date |
---|---|
JPH0638840B2 (en) | 1994-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1214129B1 (en) | Process for producing fine medicinal substances | |
US4684534A (en) | Quick-liquifying, chewable tablet | |
Lin et al. | Powder production and particle engineering for dry powder inhaler formulations | |
EP0885038B1 (en) | Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents | |
CN102883798B (en) | For the preparation of the method and apparatus of particulate and nanoparticle | |
JP3388743B2 (en) | Method for producing urea granules | |
US20020142049A1 (en) | Generation of pharmaceutical agent particles using focused acoustic energy | |
Hadiwinoto et al. | A review on recent technologies for the manufacture of pulmonary drugs | |
US20050287077A1 (en) | Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon | |
JPH07504432A (en) | pharmaceutical formulations | |
CN109310623B (en) | Nicotine particles | |
Tan et al. | Particle formation using supercritical fluids: pharmaceutical applications | |
JPS5934419B2 (en) | Method for producing urea prills and urea prills obtained by applying this method | |
JPS6373964A (en) | Freeze fine pulverization of crystal | |
US20060270561A1 (en) | Compositions for use in stored crop treatment aerosols and method and apparatus for application to stored crops | |
KR20100135901A (en) | Steroid nebuliser formulation | |
JPS62114639A (en) | Method and apparatus for preparing fine frozen particles | |
Kale et al. | Recent advancements in particle engi-neering techniques for pharmaceutical applications | |
JPS6374480A (en) | Production of frozen small particle containing cell | |
JP2539205B2 (en) | Cell disruption processing method | |
JP2528644B2 (en) | Manufacturing method of frozen cells | |
Paradkar et al. | 4 Ultrasound-Assisted Particle Engineering | |
MXPA06000606A (en) | Process for the preparation of urea granules. | |
CN220750563U (en) | Spray freeze drying device and inhalation preparation system | |
JPS6058193B2 (en) | Fluid granulation method for urea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |